Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Status:
Terminated
Trial end date:
2020-01-15
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, parallel groups Phase II trial. Patients with
platinum-sensitive advanced ovarian cancer, defined as a lack of progression by RECIST v1.1
criteria following completion of standard-of-care chemotherapy, including a minimum of 4
cycles of a platinum-containing regimen. Patients will be randomized to either the vaccine
regimen with GM-CSF adjuvant or GM-CSF adjuvant alone as a control group. Treatment will be
administered as a consolidation therapy within one year of the last administration of
platinum, targeting the first remission.